5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Low Anterior Resection Syndrome(RALARS)

• Status: Not yet recruiting
• Trial end date: 2032-12-01
• Target enrollment: 0
• Participant gender: All

Summary

5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Low Anterior Resection Syndrome(RALARS): Multicenter Randomized Controlled Trial

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Ramosetron

Criteria

Inclusion Criteria:

• mid and low rectal cancer (AV<=9cm)

• stage I, no stomy

• stage II, III, preop long-course CCRT, then ileostomy repair

• about 1 month after operation (LAR or ileostomy repair)

• major LARS

Exclusion Criteria:

• recurred rectal cancer

• stage IV

• IBD

• uncontrolled preoperative fecal incontinence or constipation